Drug Interaction in Psycho-Oncology: Antidepressants and Antineoplastics | Zendy

Cristina de Miguel | Zendy; Emília Albuquerque | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Interaction in Psycho-Oncology: Antidepressants and Antineoplastics

Author(s) -

Cristina de Miguel,

Emília Albuquerque

Publication year - 2011

Publication title -

pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.51

H-Index - 59

eISSN - 1423-0313

pISSN - 0031-7012

DOI - 10.1159/000334738

Subject(s) - sertraline , venlafaxine , fluvoxamine , mirtazapine , citalopram , pharmacology , paroxetine , drug interaction , fluoxetine , drug , escitalopram , cyp3a4 , medicine , pharmacokinetics , antidepressant , cytochrome p450 , psychiatry , anxiety , serotonin , receptor , metabolism

Although there is a growing impact of psychiatric and depressive disorders in cancer patients, literature on the idiosyncrasies of antidepressants (ADs) used in those conditions and their interactions with antineoplastic agents (ANs) is scarce. Sharing the same biotransformation pathways enhances the risk of drug interaction between ADs and ANs, specifically when compounds are inducers, inhibitors or substrates of cytochrome P450 (CYP 450). In cancer patients, such drug interactions may result in less efficacy of the drug and/or increase of their side effects. Therefore, the choice of AD should be cautious (safe and effective) and well supported. The main purpose of this review was to analyze the individual pharmacokinetic properties of the most used ADs and ANs in order to summarize the risk of possible drug interactions between them, anticipating the consequences of their coadministration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research